Ritapaola Petrelli, interviewed by the Financial Times for the "Europe’s Long-term Growth Champions” 2026 award
This moment not only celebrates our journey, but also consolidates the recent prestigious recognition as First European Company for Long-term Growth in the Health Care & Life Sciences sector in the ranking compiled by the Financial Times and Statista.
This milestone is not just a number, but confirmation that our strategic vision is a winning one, especially in a demographic context as unique as Italy’s.
Italy, with one of the oldest populations in Europe, presents challenges, but we have turned them into opportunities for growth and innovation. As the President of Kolinpharma®, Ritapaola Petrelli, pointed out:
"The ageing process is getting longer, the average age is rising. [...] That is why we develop effective nutraceuticals, able to truly support people’s wellbeing and quality of life."
“This is our mission: not only to grow as a company (with revenue of €19M last year), but to contribute actively to the quality of life of the ageing population, and of those who care for it” Ritapaola Petrelli continues.
The secret? Constant investment in Research and Development devoted to creating nutraceuticals containing unique active substances, with scientifically studied efficacy, offering relief from age-related complaints such as joint pain, menopause and cognitive decline.
Special thanks to the whole Kolinpharma® team for the great dedication it shows every day in carrying forward the company’s Mission.

















